patients. CD4+ T cells, derived from PBMCs of healthy donors, were used to obtain T-cell clones. CD4+ T-cell clones were classified on the basis of their ability to produce IFN-γ and/ or IL-17. T cell clones were polyclonally stimulated with anti-CD3/CD28. Cytokine expression was assessed with RT-PCR and production in supernatants by ELISA.

Results As previously described, IL-17A and TNF-α had a synergistic effect for both cells. Moreover, a stronger induction for IL-6 production was seen for synoviocytes compared to EC (1005 ± 22 pg/ml versus 250 ± 15 ng/ml respectively). Supernatants from activated Th1 or Th17 clones had no effect on EC. Regarding synoviocytes, supernatants from activated clones induced IL-6 and IL-8 mRNA expression with a stronger effect for Th17 cells (1000 fold versus 100 fold compared to resting synoviocytes, p = 0.045). While activated Th1 supernatants had a strong effect on EC and increased the expression of IL-6, IL-8, E-selectin, and tissue factor mRNA (98.12, 89 fold respectively, compare to control), Th17 supernatants had no effect. Activated Th1 and Th17 supernatants had the same effect on synoviocytes (254 and 754 fold compared to control). Th1 cells were more potent inducers of IL-6, IL-8 and tissue factor mRNA in EC than Th17 which had no significant effect (5, 12.5, 7.5 fold respectively compared to control). Th17 cells were most effective to stimulate IL-6 and IL-8 mRNA expression in synoviocytes compared to Th1 (100 fold versus 24 for IL-6 mRNA, p = 0.027). Anti-IL-17 antibody reduced IL-6 production from 20.0 ± 4.5 ng/ml to 13.2 ± 3.9 ng/ml (p = 0.032) in synoviocytes cultured with Th17 clones.

Conclusions While Th1 cells could be able to induce inflammatory cytokine expression in EC and synoviocytes, Th17 cells were only active to promote inflammatory expression in inflammatory cells such as synoviocytes. The effect of Th17 cells appears to depend of IL-17 and the type of stromal cells.

A3.8 EXTRATHYMIC AUTOIMMUNE REGULATOR (AIRE) EXPRESSION IN RHEUMATOID ARTHRITIS

doi:10.1136/annrheumdis-2013-203216.8

AR Noort, KPM van Zoest, MC Leibré, FP Taé, SW Tas. Division of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands

Background AIRE is a transcription factor that is involved in the negative selection of self-reactive thymocytes in the thymus. Recently, AIRE protein has also been detected in peripheral lymphoid organs, predominantly in dendritic cells (DC). In these peripheral sites, AIRE was found to regulate the expression of a group of tissue-specific antigens that is distinct from those expressed in the thymus, suggesting that peripheral AIRE may play a complementary role in tolerance induction. It is currently unknown whether AIRE may play a role in inflamed tissues, such as rheumatoid arthritis (RA) synovial tissue (ST).

Objective To document and further characterise extrathythmic AIRE expressing cells in ST and paired peripheral blood (PB) mono-nuclear cells (MCs) as well synovial fluid (SF) MCs of RA patients.

Methods ST was obtained via mini-arthroscopy from inflamed joints of RA or undifferentiated arthritis (U) patients. Expression of AIRE was evaluated using IHC and IF microscopy. AIRE expression was also investigated in PB and SF DC using flow cytometry.

Results AIRE expressing cells were detected in 80% of analysed RA ST and in contrast only in 25% of UA ST. Further characterisation using double-immunofluorescence microscopy revealed that these cells were predominantly CD1c+ myeloid (mDC). Interestingly, a significantly higher percentage of CD1c+ mDC in RA SF expressed AIRE (55 ± 5%) compared to RA PB (20 ± 5%) and healthy PB (19.7 ± 2%).

Conclusions Extrathythmic AIRE expressing CD1c+ mDCs are present in RA ST and RA SF, suggesting a role in synovial inflammation. Extrathythmic AIRE expression in RA synovial inflammation may be an attempt to control inflammation through the induction of peripheral tolerance to antigens involved in the perpetuation of the chronic inflammatory response.

A3.9 IL-17RA SIGNALLING IS ESSENTIAL FOR COLLAGEN INDUCED ARTHRITIS DEVELOPMENT

doi:10.1136/annrheumdis-2013-203216.9

1Odilia Bj Cometh, 2Adriana MC Mus, 3Patrick S Asmaawidjaja, 4Maarten D Brem, 5Franka Luk, 6Wendy Dankers, 7Rudi W Hendriks, 8Erik Loubberts. Departments of Rheumatology, *Immunology, 9Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

Introduction IL-17A plays an important role in collagen-induced arthritis (CIA). It signals through the IL-17 receptor (IL-17R) A and C heterodimer. The IL-17RA appears to be a common receptor subunit for several IL-17 cytokine family members, including IL-17A, IL-17C and IL-17F. Lack of IL-17RA signalling may therefore have a broader effect than lack of IL-17A alone. We therefore aim to determine the role of IL-17RA signalling in arthritis.

Methods Disease incidence and severity were scored in wild type (positive control), IL-17RA deficient and IL-23p19 deficient (negative control) mice in CIA. T helper cell profiles and humoral immune responses were analysed by flow cytometry and immuno-histochemistry. Serum auto-reactive IgG antibodies were measured by ELISA. Pathogenicity of T cells and total splenocytes was determined in a functional assay in vitro.

Results As expected, wild type mice developed CIA from day 21 after the first immunisation. IL-23p19 deficient mice did not develop arthritis. Interestingly, IL-17RA deficient mice were completely protected against CIA, even after a third immunisation. This is in contrast to IL-17A deficient mice, of which 20% is still susceptible to CIA. T cells in IL-17RA deficient mice display a Th2-like phenotype in CIA with higher proportions of IL-4 producing CD4 T cells. This population is distinct from IL-17A producing T cells. The shift in T cell phenotype induces a less inflammatory B cell response with fewer plasma cells in the spleen and lower pathogenic IgG2a antibody levels in serum. This is in contrast to IL-17A deficient mice and suggests that other factors involved in CD4+ T cell differentiation and pathogenicity can signal through the IL-17RA.

A3.10 IL-6 RECEPTOR BLOCKADE ENHANCES CD39+ REGULATORY T-CELL DEVELOPMENT IN RHEUMATOID ARTHRITIS AND IN EXPERIMENTAL ARTHRITIS

doi:10.1136/annrheumdis-2013-203216.10

1Allan Thiolat, 2Jerome Biton, 3Luca Sereneto, 5Yves-Marie Pers, 6Pierre Portales, 7Delphine Lemeiter, 8Patrice Decker, 9Marie-Christophe Boissier, 10Allan Thiolat, 11Jerome Biton, 12Luca Semerano, 12Yves-Marie Pers, 12Pierre Portales, 13Christian Jorgensen, 14Delphine Lemeiter, 15Patrice Decker, 16Marie-Christophe Boissier

Background Studies have demonstrated the clinical efficacy of tocilizumab, a humanised anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational approach is to determine whether IL-6 receptor blockade enhances CD39+ regulatory T-cell (CD39+ Treg) development in experimental arthritis.

Objective To determine whether IL-6 receptor blockade enhances CD39+ regulatory T-cell development in vivo.

Methods CIA was induced in IL-6Rα deficient mice, a functional antagonist of IL-6R, compared to IL-6Rα wild-type (WT) littermates. CD39+ Treg were assessed by flow cytometry and functional assays.

Results IL-6Rα deficient mice displayed an enhanced CD39+ regulatory T-cell population compared to WT mice. In vivo, IL-6Rα deficiency significantly enhanced the percentage of CD39+ Treg in the spleen and peripheral lymph nodes, compared to WT mice. This effect was also observed in vivo IL-6Rα deficiency was associated with a significant decrease in the percentage of effector T cells in the spleen and peripheral lymph nodes, compared to WT mice. In vivo, IL-6Rα deficiency was associated with a significant decrease in the percentage of effector T cells in the spleen and peripheral lymph nodes, compared to WT mice.

Conclusions IL-6 receptor blockade enhances CD39+ regulatory T-cell development in vivo. This suggests that IL-6 receptor blockade may be a potential therapeutic target for the treatment of rheumatoid arthritis.